NASDAQ:CNTG - Nasdaq - NL0014040206 - Common Stock - Currency: USD
0.325
-0.02 (-6.23%)
The current stock price of CNTG is 0.325 USD. In the past month the price decreased by -33.52%. In the past year, price decreased by -68.45%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
CI | THE CIGNA GROUP | 10.97 | 82.08B | ||
CVS | CVS HEALTH CORP | 11.71 | 79.88B | ||
LH | LABCORP HOLDINGS INC | 17.15 | 20.84B | ||
DGX | QUEST DIAGNOSTICS INC | 19.1 | 19.12B | ||
FMS | FRESENIUS MEDICAL CARE-ADR | 13.74 | 13.55B | ||
BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 148.77 | 12.18B | ||
DVA | DAVITA INC | 14.99 | 11.68B | ||
HIMS | HIMS & HERS HEALTH INC | 112 | 10.77B | ||
CHE | CHEMED CORP | 23.84 | 8.18B | ||
CRVL | CORVEL CORP | 25.97 | 5.57B | ||
OPCH | OPTION CARE HEALTH INC | 26.89 | 5.45B | ||
GH | GUARDANT HEALTH INC | N/A | 5.30B |
Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company is headquartered in Rostock, Mecklenburg-Vorpommern and currently employs 493 full-time employees. The company went IPO on 2019-11-07. The firm focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The firm's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The firm's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The firm's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.
CENTOGENE NV
Am Strande 7
Rostock MECKLENBURG-VORPOMMERN 18055 DE
CEO: Andrin Oswald
Employees: 493
Company Website: https://www.centogene.com/
Phone: 4938180113400
The current stock price of CNTG is 0.325 USD. The price decreased by -6.23% in the last trading session.
The exchange symbol of CENTOGENE NV is CNTG and it is listed on the Nasdaq exchange.
CNTG stock is listed on the Nasdaq exchange.
7 analysts have analysed CNTG and the average price target is 1.53 USD. This implies a price increase of 370.77% is expected in the next year compared to the current price of 0.325. Check the CENTOGENE NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CENTOGENE NV (CNTG) has a market capitalization of 8.97M USD. This makes CNTG a Nano Cap stock.
CENTOGENE NV (CNTG) currently has 493 employees.
CENTOGENE NV (CNTG) has a resistance level at 0.35. Check the full technical report for a detailed analysis of CNTG support and resistance levels.
The Revenue of CENTOGENE NV (CNTG) is expected to grow by 22.37% in the next year. Check the estimates tab for more information on the CNTG EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CNTG does not pay a dividend.
CENTOGENE NV (CNTG) will report earnings on 2024-09-04.
CENTOGENE NV (CNTG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.39).
ChartMill assigns a fundamental rating of 1 / 10 to CNTG. Both the profitability and financial health of CNTG have multiple concerns.
Over the last trailing twelve months CNTG reported a non-GAAP Earnings per Share(EPS) of -1.39. The EPS decreased by -6.92% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -46.05% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 83% to CNTG. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 39.38% and a revenue growth 22.37% for CNTG